InnoCare Announces Approval of Clinical Trial for Novel CDH17-Targeted ADC ICP-B208 in China

(SeaPRwire) –   BEIJING, May 06, 2026 — InnoCare Pharma (HKEX: 9969; SSE: 688428), a prominent biopharmaceutical company specializing in cancer and autoimmune disease treatments, has announced today that the Center for Drug Evaluation (CDE) under China’s National Medical Products Administration (NMPA) has granted the Investigational New Drug (IND) application to launch a clinical trial for its novel CDH17-targeted ADC, ICP-B208.

CDH17 is a calcium-dependent cell adhesion protein that plays a critical role in tumor cell growth, migration, and metastasis. Its tumor-specific expression and functional importance in cancer biology make it an appealing and distinct target for ADC therapy, which can be developed to treat gastrointestinal cancers including colorectal, gastric, pancreatic ductal adenocarcinoma, and biliary tract cancer. Currently, there are no globally approved ADCs targeting CDH17.

ICP-B208 is an innovative ADC consisting of a humanized anti-CDH17 monoclonal antibody conjugated to a potent, in-house developed payload via a protease-cleavable linker. This design delivers significantly enhanced tumor-killing effects with improved stability and safety. Preclinical studies indicate that ICP-B208 exhibits strong anti-tumor activity even in tumors with low CDH17 expression, and shows better cell-killing efficacy compared to similar drugs.

ICP-B208 is the second novel ADC to enter clinical development through the company’s in-house ADC platform, following ICP-B794—a novel B7-H3-targeted ADC. As the platform continues to evolve, the company is positioned to expand its portfolio with multiple differentiated ADC candidates.

Dr. Jasmine Cui, Co-Founder, Chairwoman, and CEO of InnoCare, stated: “The approval of ICP-B208’s clinical trial marks another milestone in our solid tumor pipeline and validates the immense drug development potential of our ADC platform. We will continue to expand our portfolio with multiple ADC candidates and bring new hope to cancer patients worldwide.”

About InnoCare Pharma

InnoCare (SSE: 688428; HKEX: 9969) is a commercial-stage biopharmaceutical company dedicated to discovering, developing, and commercializing innovative drugs for cancers and autoimmune diseases—two therapeutic areas with unmet medical needs globally. InnoCare has established comprehensive drug discovery innovation platforms. To date, the company has built a robust product pipeline including three approved drugs (orelabrutinib, tafasitamab, and zurletrectinib), over ten innovative drug candidates in clinical development, and multiple preclinical programs. InnoCare has branches in Beijing, Nanjing, Shanghai, Guangzhou, Hong Kong, and the United States. For more information, visit https://www.innocarepharma.com/en or follow us on LinkedIn.

InnoCare Forward-looking Statements

This report contains disclosures of certain forward-looking statements. Except for factual statements, all other statements are considered forward-looking—relating to our or our management’s intentions, plans, beliefs, or expectations for future events. These statements are assumptions and estimates made by our management based on their experience, knowledge of historical trends, current conditions, expected future developments, and other relevant factors. Forward-looking statements do not guarantee future performance; actual results, developments, and business decisions may differ from the expectations outlined. Our forward-looking statements are also subject to numerous risks and uncertainties that could impact our short-term and long-term performance.